Oncolytics Biotech (ONCY) Q4 2024 earnings summary

Executive summary

• Pelareorep demonstrated strong efficacy in breast, pancreatic, and anal cancers, with BRACELET-1 and GOBLET studies supporting further development and potential accelerated approval pathways.

• The company is prioritizing metastatic HR positive HER2 negative breast cancer, planning a large phase 2 registration-enabling study and seeking accelerated FDA approval if results are consistent with BRACELET-1.

• Collaborations with GCAR and PanCAN continue, with PanCAN funding a $5 million grant for pancreatic cancer research.

• A search for a new permanent CEO is ongoing, with Dr. Matt Coffey expected to support in an advisory role.

• GOBLET study data in pancreatic and anal carcinoma demonstrated promising response rates and safety, supporting continued development and potential expansion into additional indications.

Financial highlights

• Cash and cash equivalents stood at $15.9 million as of December 31, 2024, providing runway through key milestones into Q3 2025.

• Net cash used in operating activities for 2024 was $27.0 million, down from $28.4 million in 2023.

• General and administrative expenses for Q4 2024 were $3.9 million, a decrease from $4.2 million in Q4 2023.

• Research and development expenses for Q4 2024 were $4.6 million, slightly down from $4.7 million in Q4 2023.

• Net loss for Q4 2024 was $8.0 million ($0.10 per share), compared to $3.9 million ($0.05 per share) in Q4 2023; full year 2024 net loss was $31.7 million ($0.41 per share).

Outlook and guidance

• The phase 2 breast cancer study is expected to begin in H2 2025, with an 18-month enrollment period and a 6-month data maturity for PFS readout.

• Futility analysis for the breast cancer trial is anticipated 14 months after first patient enrollment.

• Initial efficacy results from the pancreatic cancer cohort are expected by year-end 2025.

• Projected cash runway extends through critical milestones into Q3 2025.

• Ongoing business development efforts are focused on securing biopharma partnerships, especially in breast cancer.